Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNAP's Pharmecuetical subsidiary:
"We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company's main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer, who will head the new subsidiary's day-to-day operations. "We believe that test/drug combinations called 'theranostics' are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company's commitment to the development of these products."
Ann
The work of Tony Frudakis:
http://www.1421.tv/pages/content/index.asp?PageID=119
Ann
A grant for DNAP, may be a reread:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
Here, too, Gratli.
Ann
I believe you're right, Dorse...
Ann
Dorsey:
"and guess who gave out the most complete picture?......."
Not sure what you mean.
Take care,
Ann
Hope that will be the case, Arch...
Ann
Arch:
It's great that DNAPrint gets 1st billing at end of article. I wonder if the impulse for a black person would be to click on "African Ancestry" instead of DNAP? Perhaps, they will look both over before deciding which test to go with? Any thoughts?
Take care,
Ann
Dorsey:
Have a good one & thanks!
Ann
DNAP attending this Conference:
http://www.theiacpconference.org/exhibitor_list.cfm
Ann
Trace Genetics - sounds impressive:
"Trace Genetics is a full service DNA laboratory dedicated to bringing you premiere services and optimal results. We are specialists in genetic identity DNA analysis with expertise in gene genealogy, forensics, molecular diagnostics and population genetics. Our eyes continually look toward innovation as we seek to pioneer new methods by which we will set the industry standard for reliability and service.
Co-founders Ripan S. Malhi and Jason Eshleman have over a decade of DNA identification experience and are considered leaders in the industry. They are two of only a handful of researchers world-wide considered to be experts in ancient DNA analysis, and have worked with ancient human and non-human DNA from several hundred to several thousand years old. They were chosen to be part of the ground-breaking Kennewick Man research team for the Department of the Interior and have worked on numerous other projects analyzing both single specimens and ancient populations. Both Dr. Malhi and Dr. Eshleman completed their doctoral research at UC Davis, where they worked extensively with the gene genealogies of Native American Peoples. Drs. Malhi and Eshleman have also benefited from the university’s 20 years of experience in primate paternity and colony management serving the NIH and other primate research facilities.
In July 2005, Trace Genetics was acquired by DNAPrint™ genomics Inc..
Ann
List of DNAP Credentials:
"DNAPrint took a significant step in pharmaceutical development in July 2005 by acquiring an 18% stake in the German pharmaceutical company Biofrontera, which also has a number of compounds under development. Biofrontera is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.
DNAPrint's first test/drug combination is PT-401, being developed in collaboration with Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC). PT-401 is a more powerful version of erythropoietin used for the treatment of anemia in renal dialysis patients (end stage renal disease). This "Super EPO" dimer protein drug is currently in pre-clinical development and will be targeted to patients with a genetic disposition indicating their propensity to have the best clinical response.
DNAPrint is also collaborating with the H. Lee Moffitt Cancer Center on the development of two other pharmacogenomic products: OVANOME™, a test for predicting an ovarian cancer patient's response to TAXOL/Carboplatin treatment, and STATINOME™, a test for predicting adverse response to cholesterol lowering medicines known as Statins."
Ann
A reminder review of DNA Phenomics:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
DNAP's on-site order form:
http://www.ancestrybydna.com/welcome/ordernow/
Ann
DNAP's order page:
http://www.ancestrybydna.com/welcome/home/
Ann
FYI:
"While the National Geographic kit analyzes deep ancestry, which can tell how an individual's distant ancestors migrated out of Africa, other tests can shed light on a person's more-recent family tree, for example, estimating the percentage of ancestry that is tied to Europe, Africa, Asia, or the Americas, or how closely related an individual is to someone else with the same last name.
FamilyTreeDNA, Relative Genetics, a genealogy company based in Salt Lake City, UT, and DNAPrint genomics, a genetics company based in Sarasota, FL, all have offered DNA tests, as well as deep ancestry tests, for several years. Interest has soared, they say, for two key reasons: testing costs have decreased and people have become more aware of the possibilities of DNA.
Ann
A little more info:
"We are particularly impressed with DOCRO's success in managing clinical trials and their ability to provide the appropriate documents required by the FDA. DOCRO's commitment to quality and integrity has facilitated multiple successful FDA submissions and eventual market introductions of diagnostic tests. DOCRO's team will be an advantage as we navigate our CD59 test through the multiple steps of the FDA process," noted Chief Executive Officer Richard Gabriel.
"After seventy successful FDA submissions, DOCRO has had diverse and extensive experience with a wide variety of immunoassays and other diagnostic tests in many medical specialties and settings. We believe we can be a knowledgeable partner with DNAPrint Pharmaceuticals in helping develop this technology to help diabetic patients further understand and manage their health and well being," commented Thomas Soriano, President and CEO of DOCRO."
Ann
Info on our purchase of DOCRO: 2/14
"DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that DOCRO, INC (DOCRO) has been retained to provide consulting and product development services to DNAPRINT PHARMACEUTICALS, Inc., its subsidiary drug and diagnostics development company. DOCRO will perform technical and clinical assistance and provide guidance on the regulatory requirements associated with the design of clinical trials necessary to commercialize DNAPrint's recently in-licensed intellectual property relating to glycated CD59.
Glycated CD59 has shown promise as a potentially highly sensitive marker of the common complications of diabetes. These complications frequently result from obstruction of the small blood vessels that provide nutrients and oxygen to organs and tissues. At least 60% of diabetic patients will develop these and other life limiting complications, including renal failure due to microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries. Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar -- glucose -- levels experienced by even well controlled diabetic patients. Current clinical diagnosis of these complications, based on symptoms or laboratory tests, often occurs only after the patient suffers irreversible consequences to their health. If the CD59 test proves to be a sensitive measure of early cellular and molecular events in the vessel damage process associated with diabetes, patients receiving the test may be treated earlier and the disease progression may be slowed or blunted"
Ann
Thanks, Yorkie...here's to a great next week!
Ann
Dorsey:
I believe it has to do w/firewall, java script, etc.
Thanks for trying
Ann
ABOUT THE PROJECT
1. What is the Genographic Project?
2. What makes this project so different?
3. How long will the project last?
4. What will the end result be?
5. Why is the focus on human migratory patterns?
6. What is the purpose of collecting DNA for the Genographic Project?
7. How does the Genographic Project differ from the Human Genome Diversity Project (HGDP) proposed over 14 years ago?
8. Why would I want to participate?
9. Are any pharmaceutical or insurance companies involved in the Genographic Project?
10. How will the Genographic Project benefit indigenous communities?
11. Has the Genographic Project received any outside review and approval?
12. Are there specific technical requirements for accessing the Genographic Web Site?
1. What is the Genographic Project?
National Geographic and IBM are embarking on a landmark five-year study that will assemble the world's largest collection of DNA samples to map how humankind populated the planet.
The Genographic Project will use sophisticated computer analysis of DNA contributed by hundreds of thousands of people—including indigenous populations and the general public—to reveal man's migratory history and to better understand the connections and differences that make up the human race.
The Genographic Project has three core components:
Field Research—The core of the project is the collection of blood samples from indigenous populations, whose DNA contains key genetic markers that have remained relatively unaltered over hundreds of generations making them reliable indicators of ancient migratory patterns. Dr. Wells and a group of 10 scientists from prominent international institutions will conduct the field and laboratory research. One additional research center will focus on analyzing DNA from ancient remains. The Waitt Family Foundation is funding this component of the Genographic Project. An international advisory board will oversee the selection of indigenous populations for testing as well as adherence to strict sampling and research protocols.
Public Participation and Awareness Campaign—The general public can take part in the project by purchasing a Genographic Project Public Participation Kit and submitting their own cheek swab sample, allowing them to track the overall progress of the project as well as learn their own migratory history. These personal results are stored anonymously to protect the privacy of participants. National Geographic will regularly update the public and the scientific community on project findings, including through the website and through National Geographic's many other media platforms worldwide.
Genographic Legacy Project—Proceeds from the sale of the Genographic Public Participation Kits help fund future field research and a legacy project, which will build on National Geographic's 117-year-long focus on world cultures. The legacy project will support education and cultural preservation projects among participating indigenous groups.
The 10 research centers are located around the world and will represent their respective regions. The centers are located in Australia (Australia/Pacific), Brazil (South America), China (East/Southeast Asia), France (Western/Central Europe), India, Lebanon (Middle East/North Africa), Russia (North Eurasia), South Africa (Sub-Saharan Africa), the United Kingdom (Western/Central Europe), and the United States (North America).
2. What makes this project so different?
Most of what we know about anthropological genetics is based on DNA samples donated by approximately 10,000 indigenous people from around the world. While this has given us a broad view of the patterns of human migration, it represents but a small sample of humanity's genetic diversity. Over the next five years, The Genographic Project will attempt to collect and analyze DNA blood samples from over 100,000 indigenous people making it the world's largest study of its kind in the field of anthropological genetics. The resulting data will map world migratory patterns dating back some 150,000 years and will fill in the huge gaps in our knowledge of humankind's migratory history. This data will eventually comprise the largest database of its kind.
In addition to the field research component, the Genographic Project is reaching out to the public. The general public around the world will be invited to participate in the study by purchasing a Genographic Public Participation Kit. By sending in a simple cheek swab sample, a participant can learn about his or her own deep ancestry while contributing to the overall Project.
3. How long will the project last?
The Genographic Project is a five year effort. The goal is to collect and genotype at least 100,000 indigenous DNA samples from around the world over that time frame.
4. What will the end result be?
The Genographic Project will result in the creation of a global database of human genetic variation and associated anthropological data (language, social customs, etc.). This database will serve as an invaluable scientific resource for the research community. Many indigenous populations around the world are facing strong challenges to their cultural identities. The Genographic Project will provide a 'snapshot' of human genetic variation before we lose the cultural context necessary to make sense of the genetic data. Among other things, we hope that the findings from the project will underscore how closely related we are to one another as part of the extended human family.
5. Why is the focus on human migratory patterns?
Scientific evidence suggests that the human species ultimately traces back to Africa. But other questions remain. For example, how did we migrate and populate the world? The Genographic Project aims to uncover some of these mysteries and discover the details of how we journeyed around the world. What impact has culture had on human genetic variation and how have cultural practices affected our patterns of genetic diversity? If we share a recent common ancestry, why do we look different from each other? At the moment, little is known about these topics.
6. What is the purpose of collecting DNA for the Genographic Project?
DNA samples are being collected to analyze specific "markers of descent" in order to probe questions about deep ancestry and historical human migration.
7. How does the Genographic Project differ from the Human Genome Diversity Project (HGDP) proposed over 14 years ago?
While the goals of the two projects overlap to some extent, there are major differences in the clarity of our mission and the way we are carrying out this project.
The Genographic Project is studying the human journey—how we are all related, and how we arrived at where we live today. There is no medical research of any kind in the Genographic Project. Also, we will not patent any genetic data resulting from the project. All the information belongs to the global community and will be released into the public domain.
Ours is a true collaboration between indigenous populations and scientists. Helping communicate their stories and promoting preservation of their languages and cultures is integral. Before any field work begins, we have been and will continue to seek advice and counsel from leaders and members of indigenous communities about their voluntary participation in the project.
In addition to answering questions of scientific interest to indigenous populations and the general public, we feel it is imperative to give something tangible back to the participating communities through Genographic's legacy project, which will include educational activities and cultural preservation projects. Proceeds from the sale of the participation kits will help fund the legacy project.
The Genographic Project will actively involve the public; we want everyone to understand the goals, methods and results.
Fourteen years ago when the HGDP was first discussed, the language of DNA and genetic anthropology was foreign to all but a few scientists. Today that language is more familiar to many of us, and many of the ethical and privacy issues are more clearly understood by the global community.
8. Why would I want to participate?
By participating in the Genographic Project, you will be part of a real-time research effort. In addition, you will have an opportunity to learn something about your deep ancestry and the migratory journey that your ancestors followed. Also, you will be contributing financially to the project. The net proceeds from the sales of the Genographic Project Public Participation Kits will help support the field research, as well as education programs and indigenous cultural preservation efforts.
9. Are any pharmaceutical or insurance companies involved in the Genographic Project?
No. The Genographic Project is supported by private foundations in conjunction with National Geographic and IBM, the project's lead partner.
10. How will the Genographic Project benefit indigenous communities?
In addition to helping to fund the field research, the Genographic Project's net proceeds from the sale of the Public Participation Kits will be directed towards cultural preservation efforts. One of the key goals of the Genographic Project is to raise awareness of the pressures indigenous groups face and to try to empower these groups. The Genographic Project's Advisory Board, comprised of respected leaders in various scientific and other fields, will provide oversight and guidance to foster community/indigenous involvement and representation.
11. Has the Genographic Project received any outside review and approval?
The Genographic Project received full approval from the Social and Behavioral Sciences Institutional Review Board (IRB) at the University of Pennsylvania Office of Regulatory Affairs on April 12, 2005. The IRB operates in compliance with applicable laws, regulations, and ethical standards necessary for research involving human participants.
12. Are there specific technical requirements for accessing the Genographic Web Site?
In order to access the Genographic Project Web site, your computer must meet the following technical specifications:
Your operating system (OS) and browser must match one of the following combinations:
Ann
1st-time problem - hmm - but, you can copy the link - I will just go ahead and copy the document.
Ann
Link didn't copy - will try again:
https://www3.nationalgeographic.com/genographic/faqs_about.html
Ann
This should answer some of the questions:
https://www3.nationalgeographic.com/genographic/faqs_about.html#Q9
Ann
DNAP & DOCRO:
http://biz.yahoo.com/iw/060214/0109692.html
Ann
Reliagene distrtibution liaison:
http://www.reliagene.com/index.asp?content_id=072604
Ann
DNAP forms Pharmaceutical subsidiary:
http://www.marketwire.com/mw/release_html_b1?release_id=97631&tsource=3
Ann
Grageful:
This is what I didn't hope to come up.
Ann
You have a good one
It was a Mac report.
http://www.investorshub.com/boards/read_msg.asp?essage_id=7283275
Let's hope this posts right - sorry- my error
Ann
Grateful, remember this?
http://www.investorshub.com/boards/read_msg.asp?message_id=8635792
Ann
OT:
"and continue to abuse myself by reading the rest."
Thanks a lot, Dorsey. - lol
Ann
Sorry, to be so redundant - lol
Ann
Looks as though you have to access it on your own.
Ann
Here's the Louisiana Serial Murders:
http://www.patriciacornwell.com/research.html
Ann
It's under "Her Research"
http://www.patriciacornwell.com/research.html
Ann
As posted by ALO on RB - impressive Patricia Cornwall site with DNAP serial killer story screen right.
http://www.patriciacornwell.com/research.html
Ann
DOCRO's Website:
http://www.docro.com/about_us.htm
Ann
Save:
OT:
I guess I do.
Take care,
Ann
Dorsey:
OT:
Enjoy your music. I'm off gambling w/some friends...
Later,
Ann